Allogene Therapeutics Inc

Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.

Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.

Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.

In its most recent quarterly, Allogene Therapeutics Inc had 30.31M in cash and cash equivalents.

Allogene Therapeutics Inc reported 123.36M in total liabilities as of the latest reported quarter, including 32.51M in current liabilities and 90.85M in non-current liabilities.

As of the latest reported quarter, Allogene Therapeutics Inc's total assets were 415.90M, consisting of 257.75M in current assets and 158.16M in non-current assets.

Allogene Therapeutics Inc reported 292.54M in total shareholders' equity as of the latest reported quarter.